A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM).
O. Yellin
No relevant relationships to disclose
J. R. Berenson
Consultant or Advisory Role - Celgene; Millennium; Ortho Biotech
Honoraria - Celgene; Millennium
Research Funding - Celgene; Millennium; Ortho Biotech
T. Kazamel
No relevant relationships to disclose
C. Chen
No relevant relationships to disclose
A. Cartmel
No relevant relationships to disclose
T. B. S. Woliver
No relevant relationships to disclose
M. S. Flam
No relevant relationships to disclose
E. N. Bravin
No relevant relationships to disclose
Y. Nassir
No relevant relationships to disclose
R. A. Vescio
No relevant relationships to disclose
R. Swift
Consultant or Advisory Role - Millennium
Honoraria - Millennium